Senescence. It’s a beautiful-sounding word whose tones suggest it should be a perfume or an essential oil. But that’s not ...

Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...

UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...

New human clinical trial proves arginine, an amino acid, can modify plaque formation on teeth, thereby protecting ...

UK-based biotechnology company Engitix Ltd. has raised a further $25 million from billionaire Michael Platt to help develop its therapies for cancer and fibrosis.

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

Detecting cancer in the earliest stages could dramatically reduce cancer deaths because cancers are usually easier to treat ...

A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together ...

A treatment that blocks an age-related protein restored cartilage in aging and injured joints by reprogramming existing cells ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...

TYBR Health has announced the first US clinical use of the collagen-based tissue protector, B3 GEL System, aimed at ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.